Skip to main content

Table 1 Baseline characteristics of the 347 patients

From: Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection

Variable   Patients (%)/median (P25–P75)a Variable   Patients (%)/median (P25–P75)
Sex Male 290 (83.6) Child class A 335 (96.5)
  Female 57 (16.4)   B 12 (3.5)
Age (years)  ≥ 60 95 (27.4) Performance status 1 144 (41.3)
   < 60 252 (72.6)   0 203 (58.2)
HBsAg Positive 300 (86.5) BCLC staging Ad 175 (50.4)
  Negative 47 (13.5)   B 17 (4.9)
Liver cirrhosis Yes 222 (64)   C 155 (44.7)
  No 125 (36) AJCC staging I 166 (47.8)
Portal vein invasion Yes 21 (6.1)   II 136 (39.2)
  No 326 (93.9)   IIIe 45 (13)
Ascites Yes 11 (3.2) CNLC staging I 291 (83.9)
  No 336 (96.8)   II 33 (9.5)
Ablation or TACE Yes 188 (54.2)   III 23 (6.6)
  No 159 (45.8) Neutrophil count   3.6 (2.56–4.72)
AFP (ng/ml)  > 400 132 (38) Lymphocyte count   1.45 (1.03–1.84)
   ≤ 400 215 (62) Platelet count   150 (109–205)
Tumor capsule Yes 304 (87.6) γ-GT   60 (36–115)
  No 43 (12.4) AST   37 (27–53)
Tumor number  ≥ 2 42 (12.1) Total bilirubin   15.2 (12–21.2)
  1 305 (87.9) Prothrombin time   11.7 (11–12.4)
Tumor size (cm)  > 5 168 (48.4) Albumin   44 (40.7–46.7)
   ≤ 5 179 (51.6) Fibrinogen   2.61 (2.13–3.27)
MVIb Yes 172 (49.6) NLR   2.44 (1.71–3.37)
  No 175 (50.4) PLR   104.46(74.69–150.52)
Cell differentiation Poor 35 (10.1) GPR   0.45 (0.22–0.88)
  Moderate 283 (81.6) ALR   26.97 (17.02–44.74)
  Well 29 (8.4) FAR   0.06 (0.05–0.08)
MKIc Yes 33 (9.5)    
  No 314 (90.5)    
  1. aP25–P75: (lower quartile—upper quartile)
  2. bMVI: microvascular invasion
  3. cMKI: multiple kinase inhibitor
  4. dNine patients with BCLC stage 0 were merged into the BCLC stage A group
  5. eFive patients with AJCC stage IV were merged into the AJCC stage III group